Search

everythinglearnresearchcommunity

for

Search:↓

GHK-Cu serums for hair growth have mixed results, with some users not seeing significant benefits. Users have tried various brands like Tricomin and Actifolic without success.

The conversation discusses the approval of Kintor Pharmaceutical's AR-PROTAC (GT20029) for clinical trials in China for acne and androgenic alopecia. One user expresses optimism about new treatments being developed and seeks clarification on how the new drug works, specifically if it temporarily degrades the AR protein to reduce DHT sensitivity in hair follicles.

An 18-year-old is using a high-dose treatment for hair loss, including 2.5 mg dutasteride, topical minoxidil, and injectable GHK-Cu, despite minimal hair loss. Many users suggest reducing the dutasteride dose due to potential side effects and recommend starting with finasteride instead.

Skin, Hair, and Nails by Pharmekal was withdrawn from the market. Users discuss alternative supplements and treatments like Minoxidil, finasteride, and RU58841.

An 18-year-old is seeking advice on their hair loss pattern and potential treatments. They are considering using Minoxidil, finasteride, and RU58841.

The conversation is about hair regrowth using high-dose dutasteride, oral minoxidil, and microneedling. Users discuss seeing tiny hairs and hope they will become terminal, with advice to use derma rolling weekly for better results.

The conversation is about finding a pure high molecular weight hyaluronic acid for the scalp after microneedling. A user suggests using a product from The Ordinary.

Stemson Therapeutics will start human trials for hair cloning in late 2025-2026. Product development is complete, and they are preparing for production and clinical trials.

Stemson Therapeutics announced a breakthrough in hair growth technology using stem cells. Users discussed the potential high cost and skepticism about the treatment's accessibility.

AHK and GHK are discussed for hair growth in the crown area, with questions about side effects and safety after microneedling. Users share experiences and concerns about these treatments.

AHK-cu peptides are discussed for hair growth, with users comparing them to GHK-cu peptides and sharing sources to buy. AHK-cu is noted as more expensive, and users express interest in finding cheaper, reliable vendors.

KX-826 is discussed as a hair loss treatment, with comparisons to finasteride. It is noted to be more expensive, harder to source, and generally used for stabilization rather than growth.

The conversation discusses using peptides BPC-157 and TB-500, combined with microneedling, to potentially enhance hair regrowth. The user plans to try BPC-157 due to its lower cost and reports of hair growth, despite limited human trials and concerns about side effects from other treatments like minoxidil and finasteride.

Exploring different treatments for hair loss, such as cosmeRNA and HMI-115 which are small interference messenger RNA that inhibits the DHT receptor and an antibody that binds to the prolactin (PRL) receptor respectively; and researching mechanism and environment of hyperresponders.

The discussion is about using ASCEplus HRLB exosomes for hair loss treatment, which combines 10 billion exosomes with growth factors, nutrients, biotin, and copper tripeptide. The treatment is expensive and typically administered via scalp injections, but in Europe, it's done with microneedling.

An 18-year-old experiencing hair loss and seborrheic dermatitis has tried finasteride, dutasteride, and various shampoos without success. They are considering anti-androgens like RU58841 and KX-826 for oil control and dandruff reduction.

A 26-year-old male experiencing hair knotting and breakage has been using finasteride for 7 months, noticing some improvement. He uses keto shampoo, conditioner, leave-in conditioner, and argan oil, and is considering adding minoxidil and vitamins for hair strength.

A 28 year old man's 18-month journey to treat his hair loss with Dutasteride, RU58841, Minoxidil, Microneedling, Nizoral and T/GEL. He experienced some side effects along the way, including translucent semen and scalp less oily.

PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.

The conversation discusses potential hair loss treatments, including Setipiprant, Bimatoprost, and Follicept. The user encourages signing up for Follicept, which may come to market soon.

Collagen, chondroitin sulfate, hyaluronic acid, and MSM are used to improve hair appearance, making it fuller, thicker, and shinier. The user noticed significant hair improvement after resuming these supplements.

Peptides like GHK-Cu, BPC-157, and TB-500 have significantly reduced hair loss, with GHK-Cu being particularly effective. The discussion also covers the high cost of these peptides and explores more affordable purchasing options.

Hair loss discussion includes treatments like hinoki tree oil and procyanidin b2. Experiences and effectiveness of these treatments are shared.

PP405 may promote short-term hair growth by pushing follicles into the growth phase, but concerns exist about long-term effects due to lack of rest phases. Users discuss various treatments like finasteride, minoxidil, spironolactone, alfatradiol, and investigational drugs like KX-826 and GT20029 for hair maintenance and regrowth.

A human trial of verteporfin, a potential treatment for hair loss, with some users noting potential improvements in scarring and overall healing compared to control areas.

Researchers at the University of Virginia discovered a new group of stem cells in hair follicles that could potentially restore hair growth. The findings suggest that activating these stem cells might offer a new way to combat hair loss, though practical treatments are still years away.

The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.

IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.

The user shared their positive experience with a hair transplant in South Korea, highlighting thorough consultations, consistent medical team involvement, and reasonable pricing. They noted good growth and natural-looking results after several months, with stem cell PRP treatment included to support graft survival.

The conversation is about Kintor's announcement indicating continued hope for their product KX-826 as a treatment for Alopecia Androgenetica. Specific treatments mentioned are Minoxidil, Finasteride, and RU58841.